(Q36161446)

12 August 2017

1 reference

title

End-stage renal disease--not an equal opportunity disease: the role of genetic polymorphisms (English)

1 reference

12 August 2017

3

Stenvinkel P

1 reference

12 August 2017

2

Lindholm B

1 reference

12 August 2017

Nordfors L

1

1 reference

PubMed ID

15953127

12 August 2017

language of work or name

English

0 references

publication date

1 July 2005

1 reference

Journal of Internal Medicine

12 August 2017

1 reference

12 August 2017

258

1 reference

12 August 2017

1

1 reference

12 August 2017

1-12

1 reference

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

12 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Genetic factors in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia--the good, the bad, and the ugly

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

The -597 G-->A and -174 G-->C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Relation of the -174 G/C polymorphism of interleukin-6 to interleukin-6 plasma levels and to length of hospitalization after surgical coronary revascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Interleukin-6 serum levels and genotypes influence the risk for myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Genetic predisposition of the interleukin-6 response to inflammation: implications for a variety of major diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Modest implication of interleukin-6 promoter polymorphisms in longevity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Novel approaches in an integrated therapy of inflammatory-associated wasting in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Cytokine gene promoter polymorphisms and mortality in acute renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

An investigation of polymorphism in the interleukin-10 gene promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Peroxisome proliferator-activated receptors: are they involved in atherosclerosis progression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Peroxisome proliferator-activated receptors in inflammation control

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Cardiac hypertrophy and remodeling in relation to ACE and angiotensinogen genes genotypes in Chinese dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Myeloperoxidase gene variation as a determinant of atherosclerosis progression in the abdominal and thoracic aorta: an autopsy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Vascular calcification: a stiff challenge for the nephrologist: does preventing bone disease cause arterial disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Why do dialysis patients develop a heart of stone and bone of china?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Gender- and age-dependent relationships between the E-selectin S128R polymorphism and coronary artery calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Haplotype analysis of the human alpha2-HS glycoprotein (fetuin) gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

The serum protein α2–Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

The variability and accurate assessment of microinflammation in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01516.X

10.1111/J.1365-2796.2005.01516.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

15953127